BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. (Q39021652)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 February 2014

Language	Label	Description	Also known as
English	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.	scientific article published on 24 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

Andrea Anichini

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Loredana Cleris

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Giuliano G Stirparo

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Antonino Carbone

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Carmelo Carlo-Stella

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

S L Locatelli

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

S Tartari

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Saba

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M Pierdominici

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 February 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1861-1871

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

https://scigraph.springernature.com/pub.10.1038/leu.2014.81

0 references

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Management of Hodgkin lymphoma in relapse after autologous stem cell transplant.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Beyond chemotherapy: new agents for targeted treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Emerging drugs for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Bcl2 family proteins in carcinogenesis and the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

The BCL-2 protein family: opposing activities that mediate cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Histone deacetylase inhibitors in lymphoma and solid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Rational combinations using HDAC inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Hodgkin's disease: establishment and characterization of four in vitro cell lies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Identification and functional characterization of DR6, a novel death domain-containing TNF receptor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Caspase-independent cell death in T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Role of Bim in diallyl trisulfide-induced cytotoxicity in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Novel agents in Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Molecular mechanisms of necroptosis: an ordered cellular explosion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Necroptosis: an emerging form of programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

EGFR signaling and drug discovery.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Tumour cell survival signalling by the ERK1/2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.81

21 January 2018

Developments in the management of Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of histone deacetylase inhibitors in combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/24561519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2014.81

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24561519%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39021652&oldid=1940279593"